TY - JOUR
T1 - Impact of angiotensin II receptor blocker therapy (olmesartan or valsartan) on coronary atherosclerotic plaque volume measured by intravascular ultrasound in patients with stable angina pectoris
AU - Ishii, Hideki
AU - Kobayashi, Masakazu
AU - Kurebayashi, Nobutake
AU - Yoshikawa, Daiji
AU - Suzuki, Susumu
AU - Ichimiya, Satoshi
AU - Kanashiro, Masaaki
AU - Sone, Takahito
AU - Tsuboi, Hideyuki
AU - Amano, Tetsuya
AU - Uetani, Tadayuki
AU - Harada, Ken
AU - Marui, Nobuyuki
AU - Murohara, Toyoaki
N1 - Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2013/8/1
Y1 - 2013/8/1
N2 - Coronary plaques can be reduced by some medications. The aim of this study was to compare the effects of 2 angiotensin II receptor blockers (olmesartan at 20 mg/day or valsartan at 80 mg/day) on coronary plaque by coronary intravascular ultrasound. One hundred hypertensive patients with stable angina pectoris who underwent elective percutaneous coronary intervention were randomly selected to receive 1 of the 2 angiotensin II receptor blockers after coronary intervention. Nontarget coronary lesions with mild to moderate stenosis were measured by volumetric intravascular ultrasound at baseline and after 6 months. After 6 months, both the olmesartan and the valsartan groups showed significant reduction of the examined coronary plaque volume (46.2 ± 24.1 mm 3 at baseline vs 41.6 ± 21.1 mm3 at 6 months: 4.7% decrease, p = 0.0002; and 47.2 ± 32.7 mm3 at baseline vs 42.5 ± 30.2 mm3 at 6 months: 4.8% decrease, p = 0.002, respectively). There was no statistically significant difference of plaque regression between the 2 groups (p = 0.96). In conclusion, there was a significant decrease from baseline in the coronary plaque volume in patients with stable angina pectoris who received olmesartan or valsartan for 6 months. In addition, there was no significant difference in the reduction of plaque volume achieved by these 2 medications.
AB - Coronary plaques can be reduced by some medications. The aim of this study was to compare the effects of 2 angiotensin II receptor blockers (olmesartan at 20 mg/day or valsartan at 80 mg/day) on coronary plaque by coronary intravascular ultrasound. One hundred hypertensive patients with stable angina pectoris who underwent elective percutaneous coronary intervention were randomly selected to receive 1 of the 2 angiotensin II receptor blockers after coronary intervention. Nontarget coronary lesions with mild to moderate stenosis were measured by volumetric intravascular ultrasound at baseline and after 6 months. After 6 months, both the olmesartan and the valsartan groups showed significant reduction of the examined coronary plaque volume (46.2 ± 24.1 mm 3 at baseline vs 41.6 ± 21.1 mm3 at 6 months: 4.7% decrease, p = 0.0002; and 47.2 ± 32.7 mm3 at baseline vs 42.5 ± 30.2 mm3 at 6 months: 4.8% decrease, p = 0.002, respectively). There was no statistically significant difference of plaque regression between the 2 groups (p = 0.96). In conclusion, there was a significant decrease from baseline in the coronary plaque volume in patients with stable angina pectoris who received olmesartan or valsartan for 6 months. In addition, there was no significant difference in the reduction of plaque volume achieved by these 2 medications.
UR - http://www.scopus.com/inward/record.url?scp=84880332660&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880332660&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2013.03.038
DO - 10.1016/j.amjcard.2013.03.038
M3 - Article
C2 - 23623047
AN - SCOPUS:84880332660
SN - 0002-9149
VL - 112
SP - 363
EP - 368
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 3
ER -